Detection of Serum Autoantibodies to Tumor Suppressor Gene P53 with a New Enzyme-linked Immunosorbent Assay in Patients with Ovarian Cancer
Overview
Authors
Affiliations
Sera from 99 ovarian cancer patients were assayed for serum autoantibodies to p53 using a newly developed enzyme-linked immunosorbent assay (ELISA). Results were compared to the investigation using the former ELISA. The incidence of autoantibodies (25%) was lower using the newly developed ELISA as compared to the previous results (41%). The results were consistent in 79% of patients (P < .001). The incidence of autoantibodies was lower in patients with complete remission (19%) as compared to that of patients with recurrence (30%) and before primary surgery (26%). No statistically significant correlation was found among p53 serum autoantibody status and tumor stage, degree of malignancy, histologic subtype, and residual tumor after primary surgery. Use of the newly developed ELISA resulted in a higher consensus between immunohistochemically negative and autoantibody negative cases. Owing to further purifying of the prepared human recombinant p53. the newly developed ELISA seems to be of higher specificity as compared to the former ELISA.
Elevation of TP53 Autoantibody Before CA125 in Preclinical Invasive Epithelial Ovarian Cancer.
Yang W, Gentry-Maharaj A, Simmons A, Ryan A, Fourkala E, Lu Z Clin Cancer Res. 2017; 23(19):5912-5922.
PMID: 28637689 PMC: 5626590. DOI: 10.1158/1078-0432.CCR-17-0284.
Garziera M, Montico M, Bidoli E, Scalone S, Sorio R, Giorda G PLoS One. 2015; 10(10):e0140351.
PMID: 26451959 PMC: 4599823. DOI: 10.1371/journal.pone.0140351.
Patient-derived tumor-reactive antibodies as diagnostic markers for ovarian cancer.
Taylor D, Gercel-Taylor C, Parker L Gynecol Oncol. 2009; 115(1):112-120.
PMID: 19647308 PMC: 2760307. DOI: 10.1016/j.ygyno.2009.06.031.
p53 autoantibodies, cytokine levels and ovarian carcinogenesis.
Tsai-Turton M, Santillan A, Lu D, Bristow R, Chan K, Shih I Gynecol Oncol. 2009; 114(1):12-7.
PMID: 19398128 PMC: 2694938. DOI: 10.1016/j.ygyno.2009.03.028.
Immunologic aspect of ovarian cancer and p53 as tumor antigen.
Nijman H, Lambeck A, van der Burg S, van der Zee A, Daemen T J Transl Med. 2005; 3:34.
PMID: 16164749 PMC: 1243238. DOI: 10.1186/1479-5876-3-34.